Objective: Our aim was to assess the role of the body mass index (BMI) in the clinical response to systemic treatment for psoriasis. Methods: A nationwide cohort study of patients receiving a new systemic treatment for plaque psoriasis at reference centres in Italy was conducted. Information was gathered through a web-based electronic form. Patients being maintained on the same medication and with data available at 8 and 16 weeks by March 31, 2007, were eligible. The outcome was a reduction in the Psoriasis Area Severity Index (PASI) of at least 75% at follow-up compared to baseline (PASI-75). Results: Out of 8,072 patients enrolled, 2,368 were eligible and analysable at 8 weeks and 2,042 at 16 weeks. PASI-75 was achieved by 819 patients (34.5%) at 8 weeks and 1,034 (50.6%) at 16 weeks. The proportion steadily decreased with increased values of BMI. Compared to normal weight (BMI = 20–24) the adjusted odds ratio for achieving PASI-75in obese patients was 0.73 (95% CI = 0.58–0.93) at 8 weeks and 0.62 (95% CI = 0.49–0.79) at 16 weeks. The impact of the BMI did not show remarkable variations according to the drug prescribed at entry. Conclusion: The BMI affects the early clinical response to systemic treatment for psoriasis.

Impact of body mass index on clinical response to systemic treatment for psoriasis. Evidence from the psocare project / L., Naldi; A., Addis; S., Chimenti; A., Giannetti; M., Picardo; C., Tomino; M., Maccarone; L., Chatenoud; P., Bertuccio; E., Caggese; PSOCARE Study, Centers; DI NUZZO, Sergio; Parma, Center. - In: DERMATOLOGY. - ISSN 1018-8665. - 217:(2008), pp. 365-373. [10.1159/000156599]

Impact of body mass index on clinical response to systemic treatment for psoriasis. Evidence from the psocare project

DI NUZZO, Sergio;
2008-01-01

Abstract

Objective: Our aim was to assess the role of the body mass index (BMI) in the clinical response to systemic treatment for psoriasis. Methods: A nationwide cohort study of patients receiving a new systemic treatment for plaque psoriasis at reference centres in Italy was conducted. Information was gathered through a web-based electronic form. Patients being maintained on the same medication and with data available at 8 and 16 weeks by March 31, 2007, were eligible. The outcome was a reduction in the Psoriasis Area Severity Index (PASI) of at least 75% at follow-up compared to baseline (PASI-75). Results: Out of 8,072 patients enrolled, 2,368 were eligible and analysable at 8 weeks and 2,042 at 16 weeks. PASI-75 was achieved by 819 patients (34.5%) at 8 weeks and 1,034 (50.6%) at 16 weeks. The proportion steadily decreased with increased values of BMI. Compared to normal weight (BMI = 20–24) the adjusted odds ratio for achieving PASI-75in obese patients was 0.73 (95% CI = 0.58–0.93) at 8 weeks and 0.62 (95% CI = 0.49–0.79) at 16 weeks. The impact of the BMI did not show remarkable variations according to the drug prescribed at entry. Conclusion: The BMI affects the early clinical response to systemic treatment for psoriasis.
2008
Impact of body mass index on clinical response to systemic treatment for psoriasis. Evidence from the psocare project / L., Naldi; A., Addis; S., Chimenti; A., Giannetti; M., Picardo; C., Tomino; M., Maccarone; L., Chatenoud; P., Bertuccio; E., Caggese; PSOCARE Study, Centers; DI NUZZO, Sergio; Parma, Center. - In: DERMATOLOGY. - ISSN 1018-8665. - 217:(2008), pp. 365-373. [10.1159/000156599]
File in questo prodotto:
File Dimensione Formato  
BMI_Psocare_Dermatology 2008.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 179.71 kB
Formato Adobe PDF
179.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2528863
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 192
  • ???jsp.display-item.citation.isi??? 171
social impact